Legend Biotech (LEGN) Revenue & Revenue Breakdown
Legend Biotech Revenue Highlights
Latest Revenue (Y)
$285.14M
Latest Revenue (Q)
$93.99M
Main Segment (Y)
Joint Steering Committee Service
Main Geography (Y)
UNITED STATES
Legend Biotech Revenue by Period
Legend Biotech Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $285.14M | 143.70% |
| 2022-12-31 | $117.00M | 30.31% |
| 2021-12-31 | $89.79M | 18.65% |
| 2020-12-31 | $75.68M | 32.15% |
| 2019-12-31 | $57.26M | 16.55% |
| 2018-12-31 | $49.13M | - |
Legend Biotech generated $285.14M in revenue during NA 2023, up 143.70% compared to the previous quarter, and up 580.35% compared to the same period a year ago.
Legend Biotech Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $93.99M | 18.28% |
| 2023-12-31 | $79.46M | -17.24% |
| 2023-09-30 | $96.01M | 30.93% |
| 2023-06-30 | $73.33M | 101.81% |
| 2023-03-31 | $36.34M | 31.49% |
| 2022-12-31 | $27.63M | 0.99% |
| 2022-09-30 | $27.36M | 128.56% |
| 2022-06-30 | $11.97M | -70.68% |
| 2022-03-31 | $40.83M | 4.70% |
| 2021-12-31 | $38.99M | 130.99% |
| 2021-09-30 | $16.88M | -16.56% |
| 2021-06-30 | $20.23M | 47.88% |
| 2021-03-31 | $13.68M | -66.45% |
| 2020-12-31 | $40.78M | 247.18% |
| 2020-09-30 | $11.75M | 1.27% |
| 2020-06-30 | $11.60M | 0.47% |
| 2020-03-31 | $11.55M | -40.64% |
| 2019-12-31 | $19.45M | 10.05% |
| 2019-09-30 | $17.67M | 75.22% |
| 2019-06-30 | $10.09M | 0.34% |
| 2019-03-31 | $10.05M | - |
Legend Biotech generated $93.99M in revenue during Q1 2024, up 18.28% compared to the previous quarter, and up 340.14% compared to the same period a year ago.
Legend Biotech Revenue Breakdown
Legend Biotech Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 | Dec 20 |
|---|---|---|
| Licensing Of Intellectual Property | $4.91M | $5.63M |
| Joint Steering Committee Service | $54.52M | $46.78M |
Legend Biotech's latest annual revenue breakdown by segment (product or service), as of Dec 21: Joint Steering Committee Service (91.75%), and Licensing Of Intellectual Property (8.25%).
Legend Biotech Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Europe | $47.87M | $15.07M | - | - | - |
| UNITED STATES | $434.71M | $234.73M | $116.60M | $86.37M | - |
| CHINA | $320.00K | $179.00K | $328.00K | $3.42M | - |
| Other Countries | - | - | $75.00K | - | - |
| North America | - | - | - | - | $75.68M |
Legend Biotech's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (90.02%), Europe (9.91%), and CHINA (0.07%).
Legend Biotech Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals | $2.25B | $420.15M |
| APLS | Apellis Pharmaceuticals | $709.95M | $176.57M |
| BPMC | Blueprint Medicines | $508.82M | $128.18M |
| ZLAB | Zai Lab | $398.99M | $100.50M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| TVTX | Travere Therapeutics | $233.18M | $62.90M |
| MDGL | Madrigal Pharmaceuticals | $180.13M | $62.17M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
| ACLX | Arcellx | $107.94M | $26.03M |
| AMLX | Amylyx Pharmaceuticals | $87.37M | $416.00K |
| STOK | Stoke Therapeutics | $36.55M | $4.89M |
| ETNB | 89bio | - | - |
| AKRO | Akero Therapeutics | - | - |
| PCVX | Vaxcyte | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| PLRX | Pliant Therapeutics | - | - |